QR-421a
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for QR-421a, covering 2022-04-20 to 2023-01-20. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) [Phase 2, Phase 3]